Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Marks & Spencer CEO Stuart Machin insisted the high street retailer – which reported a 1% year-on-year rise in clothing and ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report), boosting the price ...

"Sectors like chemicals, defence, renewables and electronics manufacturing services are poised for significant growth despite high valuations, led by scalability in business, in 2025," Satish Menon, ...

Lifecore Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Good ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...